DocWire News Editors

DocwireNews

<p>Details that have recently emerged regarding the “CRISPR babies,” human embryos that were genetically modified to be resistant to HIV <a href="https://www.docwirenews.com/docwire-pick/future-of-medicine-picks/chinese-researcher-claims-controversial-creation-of-first-gene-edited-babies/">last year</a>, are raising concerns about how this genetic modification was done. This gene-editing process was done by He Jiankui, a Chinese biophysicist who was under public scrutiny after controversially editing the genomes of human embryos, which led to the successful birth of Lulu and Nana.</p>
<p><a href="https://www.docwirenews.com/docwire-pick/first-u-s-patient-receives-crispr-gene-therapy-for-sickle-cell-disease/">CRISPR technology</a> works by allowing researchers to make genetic edits at any specific region of a genome. This genetic editing is often done to eliminate a mutation that causes a disease or to introduce a healthy copy of a gene. CRISPR usually refers to CRISPR/Cas9, a two-protein complex. Cas9 acts as the “molecular scissors” and CRISPR functions as a guide that brings the Cas9 enzyme to the correct location.</p>
<h2><strong>How the CRISPR Babies Were Modified</strong></h2>
<p>Jiankui’s work targeted the CCR5 gene, the presence of which is required for <a href="https://www.docwirenews.com/conference-coverage/treating-patients-with-hiv/">HIV</a> to penetrate white blood cells (lymphocytes) and cause infection. The CCR5 Δ32 variant is a specific mutation of the gene missing 32 nucleotides. This mutated gene occurs in some human genomes, resulting in a high level of resistance to the HIV infection due to a lack of the CCR5 receptor protein.</p>
<p>Aiming to recreate this mutation using CRISPR <a href="https://www.docwirenews.com/docwire-pick/first-u-s-patient-receives-crispr-gene-therapy-for-sickle-cell-disease/">gene therapy</a> in human embryos, Jiankui and colleagues wanted to genetically modify humans to be immune to HIV. Although the babies were born, there were several shortcomings of this endeavor.</p>
<h2><strong>Not Matching the Exact Mutation</strong></h2>
<p>One problem with their approach was that they did not perfectly recreate the Δ32 mutation, but rather, they created several other mutations of this gene with unknown effects. These mutations could yield HIV resistance, however, they could also have unpredicted consequences. Instead of testing these potential effects, the researchers recklessly implanted them into the human embryos.</p>
<h2><strong>Uneven Editing and the “Mosaic” Effect</strong></h2>
<p>Another error source in this trial could have resulted from inefficient genetic editing, resulting in an uneven distribution of modified embryo cells. This mixture of edited and unedited cells is referred to as a mosaic. Data regarding this adverse editing is still scarce, but it appears that both Lulu and Nana are mosaic. This uneven distribution decreases the likelihood of the CRISPR babies being resistant to HIV, and mosaicism risks are another factor that was ignored by the researchers.</p>
<p>CRISPR can also make unintended cuts in the genome as well in areas that have similar genetic sequences, leading to unpredictable and unwarranted outcomes. Jiankui and colleagues tested cells from the edited embryos and only reported one improper edit, however, this type of testing required sampling of the cells which were no longer part of the embryos and continued developing.</p>
<p>This means that the remaining cells in the embryos had not been tested and could have contained unintended genetic modifications. There is no way to truly predict off-target edits and mosaicism, however, therefore there will always be shortcomings in this area.</p>
<h2><strong>Risk vs. Reward</strong></h2>
<p>The editing of an embryo is difficult to justify ethically unless the benefits strongly outweigh the risks. These modifications and associated risks would not only affect the genetically modified human but all its offspring as well, reverberating through generations.</p>
<p>Despite this risk, Jiankui was not even modifying a genetic risk that these embryos had. He was not erasing a mutation that could cause a debilitating disease but was rather inducing one to potentially decrease their risk of getting HIV if exposed.</p>
<p>Although the father of these twins has HIV, there are practices in place to prevent a father with HIV from infecting their offspring, and this technique was actually used by Jiankui’s team. Ultimately, all this CRISPR editing procedure did was decrease the children’s risk of getting the disease later in life, which can be achieved through various practices such as safe sex practices and testing of blood donations.</p>
<blockquote class="twitter-tweet" data-lang="en">
<p dir="ltr" lang="en">China&#8217;s failed gene-edited baby experiment proves we&#8217;re not ready for human embryo modification <a href="https://t.co/nKNPazQ9wS">https://t.co/nKNPazQ9wS</a> <a href="https://t.co/mUvnCgDbmK">pic.twitter.com/mUvnCgDbmK</a></p>
<p>— Conversation Global (@_TCglobal) <a href="https://twitter.com/_TCglobal/status/1202918623825793025?ref_src=twsrc%5Etfw">December 6, 2019</a></p></blockquote>
<p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p>


Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

Concerning Details of Last Year's Failed CRISPR Genetic Editing of Human Embryos

Future of Medicine

Details that have recently emerged regarding the “CRISPR babies,” human embryos that were genetically modified to be resistant to HIV last year, are raising concerns about ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe